Market Research Logo

Global Intravenous (IV) Iron Drugs Market: Industry Analysis & Outlook (2017-2021)

Global Intravenous (IV) Iron Drugs Market: Industry Analysis & Outlook (2017-2021)

Iron is among the vital minerals present in the human body. It is one of the components of hemoglobin, the substance present in red blood cells that carries oxygen throughout the body through blood, and oxygen is further utilized by the cells to produce energy required to perform all the required functions. Therefore, decline in the body’s supply of iron can lead to severe problems. The balance of iron in the body primarily is a combined result of three dynamics- intake, losses and metabolic demand.

Intravenous (I.V.) treatment, in a broad sense, covers all the types of medications delivered intravenously, i.e. directly into the vein, through intravenous (I.V.) drip. Compared to the other routes of infusing medications, the intravenous route is the fastest way to deliver fluids and medications throughout the body. Also, this method ensures 100% bioavailability, which means that the chemicals delivered are fully absorbed by the body.

The report “Global I.V. Iron Drugs Market” provides a comprehensive study of iron product market and I.V. iron market globally. It also provides detailed information for key regional markets of I.V iron industry. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry, Galenica Group, AMAG Pharmaceuticals and Allergan are being profiled. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.

The key factors driving the growth of I.V. iron drugs market are growing ageing population, growing urbanization, increase in number of dialysis cases, rising healthcare expenditure and increasing life expectancy rate. Some of the noteworthy trends and developments of this industry are paradigm shift from oral iron drugs to intravenous iron drugs and introduction of first generation drugs InFeD and Dexeferrum. However, the expansion of the market is hindered by potential risks of I.V. iron.


1. I.V. Iron Market - An Overview
1.1 Irons in Human Body: An Introduction
1.2 I.V. Iron Application Areas
1.3 I.V. Iron Applications in Nephrology
Table 1: Risk Factors for CKD
1.4 Iron Deficiency - Anemia
1.5 Iron Therapies for Anemia Treatment
2. Global Iron Product Market Analysis
2.1 Global Iron Product Market by Value
Table 2: Global Iron Product Market by Value (2011-2016)
2.2 Global Iron Product Market Forecast by Value
Table 3: Global Iron Product Market Forecast by Value (2017-2021)
2.3 Global Iron Product Market by Segments
Table 4: Global Iron Product Market by Segments (2016)
3. Global I.V. Iron Drugs Market Analysis
3.1 Global I.V. Iron Drugs Market by Value
Table 5: Global I.V. Iron Drugs Market by Value (2010-2016)
3.2 Global I.V. Iron Drugs Market Forecast by Value
Table 6: Global I.V. Iron Drugs Market Forecast by Value (2017-2021)
3.3 Global I.V. Iron Drugs Market by Product Category
Table 7: Global I.V. Iron Drugs Market by Product Category (2010-2016)
3.4 Global I.V. Iron Drugs Market Share by Product Category
Table 8: Global I.V. Iron Drugs Market Share by Product Category (2016)
3.5 Global I.V. Iron Drugs Market Share by Segments
Table 9: Global I.V. Iron Drugs Market Share by Segments (2016)
4. Regional Market Analysis
4.1 The US
4.1.1 The US I.V. Iron Drug Market by Value
Table 10: The US I.V. Iron Drug Market by Value (2010-2016)
4.1.2 The US I.V. Iron Drug Market Forecast by Value
Table 11: The US I.V. Iron Drug Market Forecast by Value (2017-2021)
4.1.2 The US I.V. Iron Drug Market by Product Category
Table 12: The US I.V. Iron Drug Market by Product Category (2010-2016)
4.1.3 The US I.V. Iron Drug Market Share by Product Category
Table 13: The US I.V. Iron Drug Market Share by Product Category (2016)
4.1.4 The US Non-dialysis I.V. Iron Drug Market by Volume
Table 14: The US Non-dialysis I.V. Iron Drug Market by Volume (2010-2016)
4.1.5 The US Non-dialysis I.V. Iron Drug Market Forecast by Volume
Table 15: The US Non-dialysis I.V. Iron Drug Market Forecast by Volume (2010-2016)
4.1.6 The US Non-dialysis I.V. Iron Drug Market Share by Product
Table 16: The US Non-dialysis I.V. Iron Drug Market Share by Product (2016)
4.2 Europe
4.2.1 European I.V. Iron Drug Market by Value
Table 17: European I.V. Iron Drug Market by Value (2010-2016)
4.2.2 European I.V. Iron Drug Market Forecast by Value
Table 18: European I.V. Iron Drug Market Forecast by Value (2017-2021)
4.2.3 European I.V. Iron Drug Market by Product Category
Table 19: European I.V. Iron Drug Market by Product Category (2010-2016)
4.2.4 European I.V. Iron Drug Market Share by Product Category
Table 20: European I.V. Iron Drug Market Share by Product Category (2016)
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Growing Ageing Population
Table 21: Global Ageing Population (2007-2016)
5.1.2 Growing Urbanization
Table 22: Global Urban Population (2007-2016)
5.1.3 Increase in Number of Dialysis Cases
Table 23: Global Dialysis Patients (2012-2016)
Table 24: Global Dialysis Patients by Type (2016)
5.1.4 Rising Healthcare Expenditure
Table 25: Global Healthcare Expenditure (2007-2016)
5.1.5 Increasing Life Expectancy Rate
Table 26: Global Life Expectancy Rate (2007-2016)
5.2 Market Trends
5.2.1 Paradigm Shift from Oral Iron Drugs to Intravenous Iron Drugs
5.2.2 Introduction of First Generation Drugs InFeD and Dexeferrum
5.3 Challenges
5.3.1 Potential Risks of I.V. Iron
6. Competitive Landscape
6.1 Comparison between Injectafer, Venofer, INFeD and Feraheme
Table 27: Comparison between Injectafer, Venofer, INFeD and Feraheme
7. Company Profiles
7.1 Galenica Group
7.1.1 Business Overview
Table 28: Galenica’s Net Sales Share by Business Segments (2016)
Table 29: Galenica’s Net Sales Share by Region (2016)
7.1.2 Financial Overview
Table 30: Galenica’s Net Sales and Net Profit (2012-2016)
7.1.3 Business Strategies
7.2 AMAG Pharmaceuticals
7.2.1 Business Overview
7.2.2 Financial Overview
Table 31: AMAG Pharmaceuticals’ Revenue and Net Income (2012-2016)
7.2.3 Business Strategies
7.3 Allergan plc.
7.3.1 Business Overview
Table 32: Allergan Plc.’s Revenue Business Segment (2016)
7.3.2 Financial Overview
Table 33: Allergan Plc.’s Revenue and Net Income (2012-2016)
7.3.3 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report